• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears Cardiac and Lung AI Applications for Exo Iris Handheld Ultrasound

News
Article

The artificial intelligence (AI)-powered applications reportedly allow clinicians to diagnose pulmonary edema and measure left ventricle ejection fraction within seconds.

The Food and Drug Administration (FDA) has granted 510(k) clearance for the addition of cardiac and lung artificial intelligence (AI) applications for the Exo Iris handheld ultrasound device.

With rapid identification of B-lines, the lung AI application allows quick detection of pulmonary edema, according to Exo. Whether one is utilizing parasternal long axis (PLAX) or apical four-chamber views, Exo said the cardiac AI application enables clinicians to ascertain stroke volume and measure left ventricle ejection fraction (LVEF) in seconds.

FDA Clears Cardiac and Lung AI Applications for Exo Iris Handheld Ultrasound

Newly FDA-cleared cardio and lung AI applications for the Exo Iris handheld ultrasound device may facilitate assessments of left ventricle ejection fraction (LVEF) and pulmonary edema in seconds, according to Exo, the manufacturer of the Exo Iris device. (Images courtesy of Exo.)

Emphasizing that the AI applications have been trained over 100,000 ultrasound images, including point-of-care images taken in critical care units and emergency room settings, Exo maintained that the cardiac and lung AI applications provide real-time recognition of key imaging landmarks, even with less than perfect scans.

“Exo’s cardiac and lung AI applications are a game-changer,” said Ted Koutouzis, M.D., a clinical instructor in emergency medicine at Northwestern Medicine in Chicago. “Now I have a fast and reliable clinical tool to help easily distinguish between COPD and CHF patients for precise and timely care.”

Recent Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Expediting the Management of Incidental Pulmonary Emboli on CT
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2024 MJH Life Sciences

All rights reserved.